Skip to main content
Premium Trial:

Request an Annual Quote

Amphora Raises $20M in Series C Private-financing Round

NEW YORK, Dec. 8 (GenomeWeb News) - Amphora Discovery has raised $20 million in a Series C round of private financing led by venture capital firm the 3i Group, the company said today.

New investors in the firm included Novartis Venture Fund and Aventis Capital, the venture arms of Novartis and Sanofi-Aventis, respectively. Previous investors Arch Venture Partners, MPM Capital, Venrock Associates, and Versant Ventures also participated in the recent round of financing.

Research Triangle Park, NC-based Amphora has developed a platform for drug discovery that integrates its own compound purification, characterization, and quantification technology, microplate processing system, and Caliper Technologies' microfluidics.

Amphora offers drug firms target-based discovery and pathway profiling services based on the technology. The firm also is developing a pipeline of small-molecule therapeutics, which are currently in preclinical development.

Two years ago, Amphora raised $23 million in a Series B round of venture funding.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.